MedTrace Logo

A Study to Evaluate QTc Prolongation With Quizartinib in Healthy Subjects Under Rapid Acceleration of Heart Rate

NCT06772246 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2025-08-01

No results posted yet for this study

Summary

This study will evaluate the impact of rapid acceleration in the heart rate on the QT prolongation of quizartinib.

Conditions

  • Healthy Subjects

Interventions

DRUG

Quizartinib

Participants will receive a single oral dose of 90 mg

OTHER

Placebo

Participants will receive a single oral dose of 90 mg

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Leader · Daiichi Sankyo

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-10-24
Primary Completion
2025-06-12
Completion
2025-06-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06772246 on ClinicalTrials.gov